CT Scans, CA-125 Tests Still Routine for Monitoring Ovarian Cancer

CT Scans, CA-125 Tests Still Routine for Monitoring Ovarian Cancer
Despite no proven benefits for patients with ovarian cancer in remission, CT scans and cancer antigen 125 (CA-125) tests are still being routinely used in ovarian cancer surveillance, according to a study published in JAMA Oncology. The results of a clinical trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2009 had shown that CA-125 testing does not extend survival but increases the use of chemotherapy and decreases patients' quality of life. CT (computed tomography) scans are widely used in various medical contexts for diagnostic and monitoring purposes. The radiation used in CT scans can damage cells and have detrimental effects. CA-125 is a biomarker that may be elevated in the blood of some patients with ovarian and other types of cancers. The CA-125 is the most frequently used test to detect ovarian cancer. To evaluate the clinical impact of the results presented at the ASCO meeting, authors of the recent study “Ovarian cancer surveillance with CA-125 tests, CT scans common despite lack of proven benefit," examined the use of CA-125 testing and CT scans in clinical practice before and after 2009. The analysis included more than 1,000 women with ovarian cancer who were in clinical remission following surgery and chemotherapy. The results showed no significant differences in the percentage of women who underwen
Subscribe or to access all post and page content.

Tagged , , , , .

Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.

Leave a Comment

Your email address will not be published. Required fields are marked *